PDF
File
Beskrivning
| Land | Sverige |
|---|---|
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Calmark Sweden AB announced today that the company's diagnostics for jaundice, Neo-Bilirubin, meets the characteristics for products in low-income countries, developed by the organization NEST360 in collaboration with UNICEF. The award shows that Calmark's product is efficient, affordable, robust and easy to use.
Newborn Essential Solutions and Technologies (NEST360) is an international alliance of clinical, technical, and public health experts from 16 leading institutions, governments, and organizations. NEST360s is financed through support from e.g. Bill & Melinda Gates Foundation, CIFF, ELMA and MacArthur Foundation and the goal is to reduce infant mortality in African hospitals by 50%. The Alliance collaborates with the African governments to strengthen health systems with innovative technology, education, and policy resources.
NEST360 publishes i.a. the report "Newborn Technology Landscape" which contains a compilation of healthcare technologies suitable for low-income countries. The seventh edition (https://nest360.org/wp-content/uploads/2022/06/1_NEST360_Newborn-Technology-Landscape_7th-edition_web_06-2022.pdf) was published on June 15, where Calmark Neo-Bilirubin receives the quality stamp "NEST360 Qualified".
To evaluate MedTech products for newborn care in low-resource settings, a five-step process (https://nest360.org/technology/) with rigorous performance and usability testing is conducted. Only devices that are available for purchase and have regulatory approval are evaluated. The products that receive the quality seal "NEST360 Qualified" meet pre-defined performance metrics based on the Target Product Profiles (https://www.unicef.org/supply/documents/target-product-profile-newborn-care) developed in collaboration with UNICEF.
The 20 characteristics developed for bilirubinometers include e.g. Linear Range, Accuracy, Results Formats, Result Units, Precision, Sample, Calibration, Equipment Required, Stability & Storage, Pricing. The evaluation of Calmark Neo-Bilirubin has been performed by the Rice360 Institute for Global Health Technologies.
"We have worked really hard to develop a product that is feasible worldwide. Both in highly developed healthcare systems and in low-income countries ", says Anna Söderlund, CEO of Calmark. "The fact that we are now getting noticed and receive the quality seal "NEST360 Qualified" is a big and important milestone for us and a proof that we have succeeded!"
Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.